News about "Piramal Pharma"

Piramal Pharma Acquires 40.67 Percent Additional Stake in Yapan Bio for INR 76 Crore

Piramal Pharma acquires an additional 40.67 percent stake in Yapan Bio for INR 76 crore, raising its ownership to 74 percent and expanding its biologics Contract Development and Manufacturing Organisation (CDMO) capabilities.

Piramal Pharma | 18/08/2026 | By News Bureau |  104

Piramal Pharma Reports Q1 FY27 Results

Piramal Pharma has reported its standalone and consolidated Q1 FY27 financial results, highlighting its performance for the quarter ended June 30, 2026.

Piramal Pharma | 30/07/2026 | By News Bureau |  104

Piramal Pharma Closes US FDA Inspection at Telangana Manufacturing Facility

Piramal Pharma has announced the successful closure of a US FDA inspection at its manufacturing facility in Digwal, Telangana, after receiving the Establishment Inspection Report (EIR) from the regulator, confirming the completion of the inspection process.

Piramal Pharma | 18/05/2026 | By News Bureau |  212

Piramal Pharma Solutions Commercialises Tablet-in-Capsule Technology at Indian Manufacturing Sites

Piramal Pharma Solutions has successfully developed and commercialised a tablet-in-capsule drug delivery system in India, enabling flexible dosing, dual-release profiles and improved patient-centric oral therapies.

Piramal Pharma | 03/02/2026 | By News Bureau |  248

Piramal Pharma Acquires Global Rights to Kenalog Brand in Up to USD 100 Million Deal

Piramal Pharma has agreed to acquire the global rights to the Kenalog brand and its associated injectable corticosteroid products from Bristol-Myers Squibb in a deal valued at up to USD 100 million. The acquisition will be executed through Piramal’s wholly owned subsidiary, Piramal Critical Care B.V.

Piramal Pharma | 02/02/2026 | By Darshana |  549

Piramal Pharma Solutions Supports George Medicines in Developing its New Drug for Hypertension, WIDAPLIK

Piramal Pharma Solutions leveraged its CDMO expertise to help George Medicines develop WIDAPLIK, the first and only FDA-approved triple combination therapy for hypertension, combining telmisartan, amlodipine, and indapamide to effectively lower blood pressure.

Piramal Pharma | 01/09/2025 | By Mrinmoy Dey |  279

Piramal Pharma to Operate its Digwal Facility on Biomass Briquettes to Promote Sustainability

This achievement marks a substantial step toward Piramal's sustainability goal to reduce Scope 1 and 2 greenhouse gas (GHG) emissions by 42 percent by 2030.

Piramal Pharma | 16/01/2025 | By Aishwarya |  997

Piramal Pharma Gets SBTi Approval for its GHG Emission Reduction Targets

Piramal Pharma Ltd. has committed to reduce absolute scope 1 and 2 GHG emissions 42 percent by FY2030 from a FY2022 base year.

Piramal Pharma | 17/09/2024 | By Aishwarya |  562

Piramal Pharma Gets EIR from US FDA for Bethlehem Plant

The EIR report signifies the closure of the inspection.

Piramal Pharma | 10/11/2023 | By Manvi |  1057

Piramal Pharma gets EIR from US FDA for Sellersville, USA facility

The inspection has now been successfully closed by the US FDA

Piramal Pharma | 19/04/2023 | By Sudeep Soparkar |  986